Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Update

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) was the recipient of a large increase in short interest during the month of May. As of May 15th, there was short interest totaling 70,108 shares, an increase of 187.2% from the April 30th total of 24,410 shares. Based on an average daily trading volume, of 92,510 shares, the short-interest ratio is currently 0.8 days. Approximately 0.6% of the shares of the company are sold short.

Lixte Biotechnology Stock Performance

LIXT stock opened at $6.25 on Monday. The company has a market cap of $77.38 million, a P/E ratio of -5.53 and a beta of 1.27. The company’s 50-day moving average price is $4.01 and its 200 day moving average price is $3.74. Lixte Biotechnology has a 52 week low of $0.64 and a 52 week high of $6.50.

Lixte Biotechnology (NASDAQ:LIXT) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.18) earnings per share for the quarter.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. DRW Securities LLC increased its position in shares of Lixte Biotechnology by 11.6% in the fourth quarter. DRW Securities LLC now owns 54,126 shares of the company’s stock valued at $213,000 after buying an additional 5,645 shares in the last quarter. Geode Capital Management LLC raised its position in Lixte Biotechnology by 25.9% during the fourth quarter. Geode Capital Management LLC now owns 52,163 shares of the company’s stock worth $205,000 after acquiring an additional 10,722 shares during the last quarter. Axxcess Wealth Management LLC acquired a new position in Lixte Biotechnology during the fourth quarter worth about $54,000. XTX Topco Ltd acquired a new position in Lixte Biotechnology during the fourth quarter worth about $57,000. Finally, Renaissance Technologies LLC raised its position in Lixte Biotechnology by 47.0% during the fourth quarter. Renaissance Technologies LLC now owns 107,500 shares of the company’s stock worth $422,000 after acquiring an additional 34,350 shares during the last quarter. Hedge funds and other institutional investors own 5.10% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered shares of Lixte Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 26th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Lixte Biotechnology currently has an average rating of “Sell”.

Lixte Biotechnology Company Profile

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.